RedHill Biopharma (RDHL) Non-Current Deffered Revenue (2022 - 2023)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

RedHill Biopharma (RDHL) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $540000.0 as the latest value for Q4 2023.

• Quarterly Non-Current Deffered Revenue fell 28.0% to $540000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $540000.0 through Dec 2023, down 28.0% year-over-year, with the annual reading at $540000.0 for FY2023, 28.0% down from the prior year.
• Non-Current Deffered Revenue for Q4 2023 was $540000.0 at RedHill Biopharma, down from $750000.0 in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $750000.0 in Q4 2022, with the low at $540000.0 in Q4 2023.

Peer Comparison